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Background:Theclinicalmanifestationsof resistance to thyroidhormone (RTH)arehighly variable,
and the impact of RTH on the cardiovascular system has been poorly investigated.
Aim: The objective of the study was to evaluate the cardiovascular characteristics of 16 untreated
and asymptomatic patients with RTH compared with 16 euthyroid healthy controls to define the
cardiovascular involvement in RTH syndrome.
Patients andMethods: Sixteen untreated and asymptomatic RTH patients (eightmales; aged 33
12 yr, range 21–45 yr) and 16 controls (nine males; aged 33 5 yr, range 24–42 yr) were enrolled.
Clinical data, thyroid status, and echocardiographic results were recorded.
Results:Heart ratewas comparablewith thatof controls,whereasarterialpressurewashigher than
controls. Mean interventricular septum diastolic thickness andmean left ventricular (LV) posterior
wall diastolic thickness were significantly lower in RTH patients than controls with a consequent
significant decrease of the mean LV mass and LV mass indexed by body surface area. Patients also
had abnormalities of myocardial relaxation as indicated by a significant increase of peak A and
consequent reductionof theearly to late ratio. Finally, systemicvascular resistancewas significantly
higher in RTH patients than controls.
Conclusions: Our results suggest the presence of cardiovascular alterations in asymptomatic and
untreated RTHpatients similar to those reported in hypothyroid patients. Our strict selection likely
created a bias in the inclusion of a particular type of RTH patients, who could represent a minority
of patients with RTH. However, no correlation was found between the type of mutation and
cardiovascular characteristics of RTH patients. (J Clin Endocrinol Metab 94: 2812–2816, 2009)
Resistance to thyroid hormone (RTH) is a rare (probably oneper 50,000 live births), dominantly inherited condition of
altered tissue responsiveness to thyroidhormone (TH), biochem-
ically characterized by elevated serum free T4 (FT4) and free T3
(FT3) concentrations, in the presence of nonsuppressed levels of
TSH (1–7).Most patientswithRTHare heterozygous for a point
mutation in the ligand-binding domain of the thyroid hormone
receptor (TR)- gene. The mutations may cause either reduced
affinity for T3 or impaired interaction with one of the cofactors
(coactivators and corepressors) that mediate TH actions (8). As
a result, the mutant TR interferes with the function of normal
TRs (dominant negative effect), which explains the dominant
mode of inheritance of this syndrome.
In the past, subjects with RTH who clinically appeared to be
euthyroid were formerly classified as having generalized resis-
tance to TH. On the contrary, subjects who clinically appeared
to be hyperthyroid were classified as having selective pituitary
resistance to TH, regardless of the TH level (6, 7). Currently this
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subclassification does not have a logical basis (9). Indeed, the
clinical manifestations of RTH are highly variable across RTH
families and within the same family, probably because of the
heterogeneity of the many factors that modulate the receptor-
dependent action of TH (8, 9). Therefore, RTH syndrome is
characterized by a variable clinical phenotype (7) as well as the
paucity of specific clinical manifestations (1, 9).
Different isoforms of TR (TR1, TR2, and TR1) are ex-
pressed in the heart; they regulate the expression of different
genes and encode both structural and regulatory proteins (8).
The effects of mutant TR on the cardiovascular system have
been widely studied in animal models (10–16). However, few
studies have evaluated the cardiovascular system in patientswith
RTH (17, 18). Ciulla et al. (17) evaluated the derived collagen
volume fraction (dCVF) (an echocardiographic index of the col-
lagen) in patients with RTH and thyroid dysfunctions identified
by videodensitometry. They showed that dCVF was lower in
hyperthyroid patients and higher in hypothyroid patients than in
controls. The RTH patients had a pattern intermediate between
those of hypothyroid patients and euthyroid controls, i.e. the
dCVF was slightly increased, which suggests that mutant TR
exerts an inhibitory effect on wild-type TR in the heart of these
patients.Kahaly et al. (18) evaluated cardiovascular involvement
in a large RTH group with a wide age range and heterogeneous
clinical manifestations (with and without thyrotoxic cardiovas-
cular symptoms) by Doppler echocardiography and compared
their results with those of hypothyroid, hyperthyroid, and eu-
thyroid subjects. RTH patients showed alterations of cardiovas-
cular parameters, resembling those found in hyperthyroid pa-
tients (cardiac output and stroke volume, isovolumic relaxation,
and deceleration times), whereas other parameters [diastolic and
systolic diameters of left ventricular (LV), shortening and ejec-
tion fractions] were comparable with those of controls. This
studywas the first to highlight the heterogeneous cardiovascular
phenotype in RTH patients, suggesting an incomplete cardiac
response to TH in RTH syndrome (18–20).
On this basis, the aim of our study was to select a homoge-
neousRTHgroupwithout thyrotoxic cardiovascular symptoms,
untreated with thyroid or cardiovascular drugs, in an attempt to
clarify the cardiovascular characteristics of asymptomatic RTH
patients.
Patients and Methods
Sixteen nonsmoking, sedentary, patients with RTH (eight men and
eight females; aged 33 12 yr, range 21–45 yr) and 16 nonsmoking,
sedentary, and healthy euthyroid controls (nine men and seven fe-
males; aged 33  5 yr, range: 24–42 yr) entered the study after having
given informed consent. The diagnosis of RTH was based on the coex-
istence of elevated free TH levels, TSH concentrations in the normal
range, no hyperthyroid manifestations, and the absence of pituitary le-
sions at magnetic resonance imaging (1–4). Six RTH patients had a
goiter. None of the RTH subjects showed cardiovascular symptoms or
used cardiovascular drugs. None of the RTH patients was submitted to
thyroidectomy or received thyroid hormone or antithyroid drugs. In
these patients, the genetic analyses were performed at the University of
Milan (Italy). Exons 9 and 10 of the TR gene, including splicing
signals and the flanking intronic regions of each intron, were ampli-
fied by PCRs (21). DNA sequences from each amplified fragmentwere
analyzed with the Taq polymerase-based chain terminator method,
using the specific TR forward and reverse primers (12). Seven mu-
tations were found: R243Q (two patients), A317T (one patient),
R338W (two patients), G344E (two patients), V349L (four patients),
R438C (one patient), E445K (one patient). No mutations were found in
three RTH subjects. Healthy euthyroid volunteers recruited among the
staff and their relatives of our departments served as controls.
On the morning of the study day, participants reported to the labo-
ratory after an overnight fast. Height and weight were measured, and
venous blood was sampled for assessment of thyroid status by using a
commercially available kit (Axsym System; Abbott Laboratories Diagnos-
ticsDivision,AbbottPark,CA),according to the followingreferenceranges:
serum TSH, 0.26–4.2 mU/liter; serum FT4, 9–20 pmol/liter; serum FT3,
3.8–8 pmol/liter). Participants then underwent cardiac assessment.
Doppler echocardiography
The same investigator, blinded to the subject’s clinical data, evaluated
echocardiographic traces, and two blinded experienced echocardio-
graphists read the echocardiographic records. Echocardiographic exam-
inationswere carried outwith patients in a partial left decubitus position
by a Vivid Seven AB Sound machine (GE, Horten, Norway) equipped
with a 2.5-MHz phased-array transducer with harmonic capability, ac-
cording to theAmerican Society of Echocardiography recommendations
(22). Three cardiac cycles were averaged formeasurements.Mean blood
pressure and pulse pressure were calculated from systolic and diastolic
blood pressure, which were measured three times in the left arm by
indirect cuff sphygmomanometry after the echocardiographic study,
with subjects in supine decubitus (22).
A standard 12-lead electrocardiogram was obtained in each patient.
Evidence of LV hypertrophy and conduction and repolarization abnor-
malities was sought (23). LV M-mode measurements of wall thickness
and end-diastolic and end-systolic diameters were obtained according to
thePennconvention (24) andused to calculate relativewall thickness and
LVmass and to estimate LV end-diastolic and end-systolic volumes with
the formula of Teichholz et al. (25). The latter estimates were used to
derive LV stroke volume and ejection fraction and to compute cardiac
output and systemic vascular resistance according to standard for-
mulae (26). LV diastolic function was assessed in the apical four-
chamber view. Early and late transmitral peak flow velocities from
pulsed-wave Doppler imaging were measured as previously reported
(27). The ratio of pulse pressure to stroke volumewas used to estimate
total arterial stiffness (28).
Statistical analysis
The statistical analysis was performed using SPSS (version 9.0.1 for
Windows;Chicago, IL).Data in the text and tables are expressed asmean
value and SD. The two-tailed unpaired Student’s t test was used to com-
pare continuous variables inRTHpatients and control subjects.P0.05
was considered statistically significant.
Results
Patients with RTH (19, 20, 29, 30) and controls were matched
by sex, age, and anthropometry, although bodyweight and body
surface area were slightly lower in the former. As expected, RTH
patientshadsignificantlyhigherserumlevelsofFT4andFT3associated
withmeanTSHvalues inthenormalrange(Table 1).Nocorrelation
was found between cardiovascular features and type of mutation.
At rest, heart rate was similar in RTH patients and controls.
However, RTH patients had higher systolic, diastolic and mean
arterial pressure than controls but similar pulse pressure. In par-
ticular, five patients (31%) had arterial blood pressure in the
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hypertensive range (140/90 mm Hg) (Table 2). The LV end-
diastolic diameter index was marginally higher in RTH patients
than controls, whereas the LV end-diastolic wall thickness index
(evaluated as themean value of interventricular septum and pos-
terior wall) was lower. Accordingly, the LV mass index and rel-
ative wall thickness were slightly but significantly lower in RTH
patients (Table 2). Although in normal range, the level of global
LV systolic functionwas lower in RTHpatients than in controls,
as indicatedby the higherLVend-systolic diameter index and the
lower LV ejection fraction. Nevertheless, the global LV perfor-
mance, as expressed by the stroke index, did not differ between
the two groups (Table 2).
The transmitral in flow pattern was normal in both RTH
patients and controls, although the early to late peak flow ve-
locity ratio (E/A) of the former was significantly lower, mostly
due to a consistent increase in the late component. Indeed, the
deceleration time of the early transmitral inflow was shorter in
RTH patients, thereby suggesting a mild to moderate global LV
diastolic dysfunction (pseudonormalization) in these patients
(Table 2). Finally, although the cardiac index and total arterial
stiffness (estimated by the pulse pressure to stroke index ratio)
were similar in the two groups, the systemic vascular resistance
index was higher in RTH patients than in controls (Table 2).
Discussion
In this case-control study, we assessed cardiac morphology and
function in 16 patients with RTH compared with euthyroid
healthy controls. We selected a homogeneous RTH group of
patients without cardiovascular symptoms and untreated with
thyroid or cardiovascular drugs to assess the cardiovascular re-
sponse to TH in RTH syndrome. Our results indicate that this
dominantly inherited condition of altered tissue responsiveness
to TH is associated with measurable alterations of LV charac-
teristics and circulatory function. These findings reinforce the
concept that TH plays an important physiologic role in the car-
diovascular system.
Our RTH patients did not have cardiovascular symptoms
(palpitations, dyspnea at rest and after exercise), and their heart
rate was comparable with control group; this could possibly be
a consequence of our inclusion criteria. The percentage of RTH
patients showing tachycardia is highly variable in various re-
ports. We found that 75–94% of RTH patients had tachycardia
in a previous article (7), whereas Brucker-Davis et al. (6) found
a comparable resting heart rate between RTH patients and con-
trols. Moreover, resting tachycardia was found in 16% of RTH
patients with a percentage similar to that of controls (6); these
results could be explained by the complex direct and indirect
actions of TH on the heart. In particular, this seems to coincide
with the report of a normal heart rate linked to expression of
different ion channels in the heart in animal models. In partic-
ular, TRPV mouse, an animal model of RTH, showed de-
creased myocardial contractility and heart rate accompanied
by decreased expression of the pacemaker-related gene hy-
perpolarization-activated cyclic nucleotide-gated 4 (15). This
gene encodes channels responsible for the slow component of
hyperpolarization-activated current, which contributes to pace-
maker activity (30). Moreover, the expression of the pacemaker
channel hyperpolarization-activated cyclic nucleotide-gated 2
was low in hypothyroid mice but normal in transgenic mice re-
sistant to TH (16). However, it must be underlined that the
TRPV mouse is homozygous, whereas RTH patients are het-
erozygous. To clarify the influence of TR on cardiac function,
another study evaluated the cardiovascular parameters in TR
TABLE 1. Demographics and thyroid status of RTH patients
and control subjects
Control
subjects
(n  16)
RTH
patients
(n  16)
P
value
Sex (male/female) 8/8 9/7 NS
Age (yr) 33  5 33  12 NS
Height (cm) 167  7 165  5 NS
Weight (kg) 66  11 60  10 NS
BMI (kg/m2) 23  3 22  2 NS
BSA (m2) 1.73  0.17 1.65  0.17 NS
TSH (mU/liter) 1.7  0.9 2.3  2.2 NS
FT4 (pmol/liter) 15  3 39  22 0.05
FT3 (pmol/liter) 6  1 16  12 0.05
Data are mean  SD. BMI, Body mass index; BSA, body surface area; NS, not
statistically significant.
TABLE 2. Cardiovascular characteristics of RTH patients and
control subjects
Control
subjects
(n  16)
RTH
patients
(n  16)
P
value
HR (bpm) 78  7 80  15 NS
SBP (mm Hg) 117  7 124  9 <0.05
DBP (mm Hg) 73  8 81  9 <0.01
MAP (mm Hg) 87  7 95  8 <0.01
PP (mm Hg) 44  7 43  8 NS
LVEDDi (mm/m2) 27.7  3.4 28.7  3.0 NS
LVESDi (mm/m2) 16.9  2.4 18.7  2.3 <0.05
LVEDWTi (mm/m2) 5.2  0.6 4.6  0.6 <0.01
LVMi (g/m2) 85  12 69  14 <0.01
RWT 0.38  0.05 0.32  0.04 <0.001
LVEF (%) 69  6 63  7 <0.05
SI (%) 42  8 40  8 NS
E (cm/sec) 77  11 70  18 NS
A (cm/sec) 48  8 58  15 <0.05
E/A (kg) 1.6  0.2 1.3  0.4 <0.01
E-dt (msec) 144  19 123  14 <0.01
CI (liters/m2) 1.73  0.17 1.65  0.17 NS
SVRi (dyne  sec/cm5  m2) 744  160 949  253 <0.05
PP/SI (mm Hg/ml  m2) 1.09  0.32 1.12  0.26 NS
Data are mean  SD. The bold numbers indicate the parameters that are
statistically significant between the two groups studied. HR, Heart rate; SBP,
systolic blood pressure; DBP, diastolic blood pressure; MAP, mean arterial
pressure; PP, pulse pressure; LVEDDi, left ventricular end-diastolic diameter index;
LVESDi, left ventricular end-systolic diameter index; LVEDWTi, left ventricular
end-diastolic wall thickness index (as mean value of interventricular septum and
posterior wall); LVMi, left ventricular mass index; RWT, relative wall thickness;
LVEF, left ventricular ejection fraction; SI, stroke index; E, early transmitral peak
inflow velocity from pulsed-wave Doppler imaging; A, late transmitral peak
inflow velocity from pulsed-wave Doppler imaging; E-dt, deceleration time of the
early transmitral inflow from pulsed-wave Doppler imaging; CI, cardiac index;
SVRi, systemic vascular resistance index; PP/SI, pulse pressure/stroke index (total
arterial stiffness); NS, not statistically significant.
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337T, a transgenicmousemodel with heterozygous cardiac-spe-
cific expression of mutant TR. TR 337T mice showed a re-
duced heart rate and a prolongation of electrocardiogram inter-
vals comparable with the results found in hypothyroid mice and
a decreased myocardial contractility, suggesting an impairment
of cardiac-specific genes regulated by TH. In particular, the TR
337Tmice showed a hypothyroid pattern ofmyosin heavy chain
gene expression (14).
However, we found that mean interventricular septum dia-
stolic thickness and mean LV posterior wall diastolic thickness
were significantly lower in RTH patients than controls. Conse-
quently, themeanLVmass andLVmass indexwere significantly
decreased, suggesting the presence of reduced TH effects during
heart development. Indeed, TH can stimulate myocardial
growth (32, 33), and an increase of LV mass has been reported
in hyperthyroid patients (20, 34–36). However, the effect of TH
on myocardial growth/gene expression is result of the comple-
mentary and antagonistic actions of the three TR isoforms found
in the heart. TR seems to inhibit activation of p38 (37), which
is frequently associated with cardiac hypertrophy, whereas pro-
longed TH absence significantly reduces cardiomyocyte diame-
ter (38). In animal models of RTH, mutant TR prevented TH-
induced cardiac hypertrophy (39, 40), suggesting that it
interfered with the function of normal TR and induced hypo-
thyroidism in the heart of the transgenicmice. Finally, studies of
the genomic effects of TH on the cardiovascular system
showed that RTH and hyperthyroid hearts were molecularly
different. Indeed, RTH mice had a discordant cardiac expres-
sion of the T3-responsive gene compared with the wild-type,
which suggests inappropriate regulation of T3-modulated
genes in RTH syndrome (41).
Furthermore, myocardial relaxation was deranged in our
RTH patients. In fact, they had a significant increase of peak A
and consequent reduction of the E/A ratio, like patients with
overt and subclinical thyroid hormone deficiency (27). These
abnormalities in subclinical and overt hypothyroidism result
from impaired diastolic function related to the reduced sarco-
plasmic reticulum calcium-ATPase activity with consequent im-
pairment of ventricular diastolic function caused by low circu-
lating levels of TH (19, 20).
Finally, systemic vascular resistance was significantly higher
in our RTH patients than in the control group, which indicates
a reduced action of TH in the vascular system. Indeed, TH di-
rectly affects arterial smoothmuscle relaxation, which leads to a
reduction in systemic vascular resistance (29, 42–44). Further-
more, endothelium-dependent vasodilatation and nitric oxide
availability were reduced hypothyroid rats and humans (30).
Our results are apparently different from a previous study by
Kahaly et al. (18) inwhich anheterogeneousRTHgroup showed
some cardiovascular alterations similar to those found in hyper-
thyroid subjects, whereas other cardiovascular parameters were
comparable with controls. In fact, it is difficult to compare our
patients with the RTH group evaluated by Kahaly et al. because
we used different selection criteria. Indeed, the RTH group by
Kahaly et al. included patients with and without thyrotoxic car-
diovascular symptoms, somepatients treatedwith levothyroxine
or antithyroid drugs and patients with a wide age range, includ-
ing children. Furthermore, Kahaly et al. only compared the data
of two distinct RTH groups (with and without thyrotoxic car-
diovascular symptoms) without comparing them to euthyroid
subjects; they compared the results of the entire RTH group
only with those of euthyroid, hypothyroid, and hyperthyroid
subjects. Interestingly, this study led us to try to clarify the
cardiovascular characteristics of asymptomatic RTH patients
compared with a group of well-matched euthyroid controls.
Therefore, we selected a homogeneousRTHgroup of young and
middle-aged patients (age range 21–45 yr), without thyrotoxic
cardiovascular symptoms and untreated with thyroid or cardio-
vascular drugs. Our strict selection criteria likely created a bias
in the inclusion of a particular type of RTH patients, who could
represent a minority of patients with RTH. In fact, the type of
mutations in our patients are different from those reported by
Kahaly et al.; indeed, 10 of our subjects with RTH had R243Q,
A317T, G344E, V394L, and E445Kmutations, which were not
present in any of the patients of Kahaly et al. Only three of our
patients shared the same mutations as those reported by Kahaly
(R338W and R438C). However, interestingly, in accordance
with the results reported by Kahaly et al., we found no correla-
tion between the type of mutation and cardiovascular charac-
teristics of RTH patients.
These results could be the consequence of the characteristic
phenotypic variability of RTH syndrome, which is related to
aspects different from the TRmutations.Moreover, clinical fea-
tures of RTH can differ among affected individuals of a kindred
harboring the same mutation (1, 2, 4). Furthermore, genetic
analyses have demonstrated different mutations in patients with
the same clinical phenotype (21). There is a significant temporal
variation in clinical signs and in parameters of TH action in the
same individuals (7). Therefore, the difference of results in two
studies seems to confirm the absence of specific and diagnostic
clinical characteristic and the extreme variability and heteroge-
neity of clinical manifestations in RTH syndrome.
In conclusion, our results support the concept that TH plays
an important physiological role in the development of the car-
diovascular system and suggest the presence of cardiovascular
alterations in untreated and asymptomatic RTHpatients similar
to those reported in hypothyroid patients.
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